Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 1787-1796

  Huo, Xiaochuan ^a   Li, Youxiang ^a   Jiang, Yuhua ^a   Sun, Xiaoyun ^b   Gu, Lixue ^b   Guo, Wenshi ^b   Sun, Dapeng ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Age related macular degeneration (AMD); Choroidal neovascularization (CNV); Laser burn (LB); Macrophages; Placental growth factor (PLGF); Vascular endothelial growth factor A (VEGF A)

Indexed keywords

LECTIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; PLACENTA PROTEIN;

ANIMAL CELL; ARTICLE; CHOROID VASCULARIZATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INJURY; FEMALE; FLOW CYTOMETRY; LASER COAGULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; C57BL MOUSE; CHOROIDAL NEOVASCULARIZATION; CYTOLOGY; DISEASE MODEL; EYE; GENETICS; LASER; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION RESPONSE;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EYE; FEMALE; LASERS; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84926190049     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373990     Document Type: Article

References (36)

1. Campochiaro PA: Ocular neovascularization. J Mol Med (Berl) 2013;91:311-321.
2. Cai X, Sezate SA, McGinnis JF: Neovascularization: Ocular diseases, animal models and therapies. Adv Exp Med Biol 2012;723:245-252.
3. Bradley J, Ju M, Robinson GS: Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007;10:141-148.
4. Campochiaro PA: Gene therapy for ocular neovascularization. Curr Gene Ther 2007;7:25-33.
5. Wolf A, Thurau S, Kook D, Hoeing A, Priglinger S, Kampik A, Haritoglou C: Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation. Acta Ophthalmol 2010;88:e295-296.
6. Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S: Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2009;127:275-281.
7. Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU, Tubingen Bevacizumab Study G, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S: Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-790.
8. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, Group FS: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the focus study. Arch Ophthalmol 2006;124:1532-1542.
9. Pieramici DJ, Avery RL: Ranibizumab: Treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 2006;6:1237-1245.
10. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group AS: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
12. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
13. Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, Gaffar I, Shiota C, Gittes GK: Pancreatic duct cells as a source of vegf in mice. Diabetologia 2014;57:991-1000.
14. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, Prasadan K, Shiota C, Gittes GK: Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem 2013;288:8636-8646.
15. Ferrara N, Gerber HP, LeCouter J: The biology of vegf and its receptors. Nat Med 2003;9:669-676.
16. Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H: Pten regulates angiogenesis through pi3k/akt/vegf signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 2009;331:161-171.
17. Cabebe E, Fisher GA: Clinical trials of vegf receptor tyrosine kinase inhibitors in pancreatic cancer. Expert Opin Investig Drugs 2007;16:467-476.
18. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS, Reber HA: Vegf antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 2005;137:192-199.
19. Mao D, Zhang Y, Lu H, Zhang H: Molecular basis underlying inhibition of metastasis of gastric cancer by anti-vegfa treatment. Tumour Biol 2014;35:8217-8223.
20. Zhou X, Qi Y: Plgf inhibition impairs metastasis of larynx carcinoma through mmp3 downregulation. Tumour Biol 2014;35:9381-9386.
21. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
22. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, Fleet C, Tritsaris K, Dissing S, Leboulch P, Cao Y: Placenta growth factor-1 antagonizes vegf-induced angiogenesis and tumor growth by the formation of functionally inactive plgf-1/vegf heterodimers. Cancer Cell 2002;1:99-108.
23. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
24. Hasegawa E, Oshima Y, Takeda A, Saeki K, Yoshida H, Sonoda KH, Ishibashi T: Il-27 inhibits pathophysiological intraocular neovascularization due to laser burn. J Leukoc Biol 2012;91:267-273.
25. Kanai T, Uraushihara K, Totsuka T, Nemoto Y, Fujii R, Kawamura T, Makita S, Sawada D, Yagita H, Okumura K, Watanabe M: Ameliorating effect of saporin-conjugated anti-cd11b monoclonal antibody in a murine t-cell-mediated chronic colitis. J Gastroenterol Hepatol 2006;21:1136-1142.
26. Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM: Anti-inflammatory m2, but not pro-inflammatory m1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109-118.
27. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, Machein MR: Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008;68:7342-7351.
28. Shen J, Xie B, Dong A, Swaim M, Hackett SF, Campochiaro PA: In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci 2007;48:4335-4341.
29. Adini A, Kornaga T, Firoozbakht F, Benjamin LE: Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-2752.
30. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, Song Z, El-Gohary Y, Prasadan K, Shiota C, Gittes GK: M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A 2014;111:E1211-1220.
31. Chen Y, Jiang T, Mao A, Xu J: Esophageal cancer stem cells express plgf to increase cancer invasion through mmp9 activation. Tumour Biol 2014;35:12749-12755.
32. Kaiser RS, Berger JW, Maguire MG, Ho AC, Javornik NB, Choroidal Neovascularization Prevention Trial Study G: Laser burn intensity and the risk for choroidal neovascularization in the cnvpt fellow eye study. Arch Ophthalmol 2001;119:826-832.
33. Gregg AJ, Schenkel AR: Cloning and structural analysis of equine platelet endothelial cell adhesion molecule (pecam, cd31) and vascular cell adhesion molecule-1 (vcam-1, cd106). Veterinary immunology and immunopathology 2008;122:295-308.
34. Lechleitner S, Gille J, Johnson DR, Petzelbauer P: Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (cd106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway. J Exp Med 1998;187:2023-2030.
35. Halama T, Staffler G, Hoch S, Stockinger H, Wolff K, Petzelbauer P: Vascular-endothelial cadherin (cd144)-but not pecam-1 (cd31)-based cell-to-cell contacts convey the maintenance of a quiescent endothelial monolayer. Int Arch Allergy Immunol 1999;120:237-244.
36. Zheng H, Shen CJ, Qiu FY, Zhao YB, Fu GS: Stromal cell-derived factor 1alpha reduces senescence of endothelial progenitor subpopulation in lectin-binding and dildl-uptaking cell through telomerase activation and telomere elongation. J Cell Physiol 2010;223:757-763.